SCHEMBL348963

SCHEMBL348963

COC(=O)Cc1cc(OC)cc(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.62
GAA P10253 2/20 0.53
KDM4E B2RXH2 1/20 0.53
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 4/20 0.47
GFER P55789 1/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
MAPK8 P45983 1/20 0.47
MEN1 O00255 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GLS O94925 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14626264 0.89 HSP90AB1 (0.51) HSP90AB1GAAKDM4ECYP4F2CYP4A11
SCHEMBL17385731 0.89 HSP90AB1 (0.55) HSP90AB1GAAKDM4ECYP4F2CYP4A11
SCHEMBL14420070 0.89 HSP90AB1 (0.55) HSP90AB1GAAKDM4ECYP4F2CYP4A11
SCHEMBL2977953 0.89 HSP90AB1 (0.76) HSP90AB1GAAKDM4ECYP4F2CYP4A11
SCHEMBL1868343 0.87 HSP90AB1 (0.53) HSP90AB1GAAKDM4ECYP4F2CYP4A11
SCHEMBL7802725 0.87 HSP90AB1 (0.53) HSP90AB1GAAKDM4ECYP4F2CYP4A11
SCHEMBL18554389 0.87 HSP90AB1 (0.53) HSP90AB1GAAKDM4ECYP4F2CYP4A11
SCHEMBL18554422 0.84 HSP90AB1 (0.50) HSP90AB1GAAKDM4EL3MBTL1ALDH1A1
SCHEMBL21891794 0.84 HSP90AB1 (0.75) HSP90AB1GAAKDM4ECYP4F2CYP4A11
SCHEMBL14420104 0.83 PTGS2 (0.54) HSP90AB1CYP4F2CYP4A11GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112142733-A Synthetic route of pan FGFR covalent inhibitor PRN1371 湖南师范大学 2020-12-29 CN claimed
EP-3334735-B1 PROCESSES FOR PREPARING AN FGFR INHIBITOR PRINCIPIA BIOPHARMA INC (US) 2025-08-13 EP disclosed
US-12281110-B2 Processes for preparing an FGFR inhibitor PRINCIPIA BIOPHARMA, INC. (US) 2025-04-22 US disclosed
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMAC, INC. (US) 2024-12-10 US disclosed
US-20240309000-A1 Process for Preparing an FGFR Inhibitor PRINCIPIA BIOPHARMA, INC. (US) 2024-09-19 US disclosed
US-11999732-B2 P2X3 receptor antagonists RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) 2024-06-04 US disclosed
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-03-21 US disclosed
CN-112584898-B P2X 3 Receptor antagonists 瑞蔻达蒂化学和制药工业股份有限公司 2024-01-26 CN disclosed
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-01-17 US disclosed
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2022-11-03 US disclosed
EP-1581531-A1 PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS F. Hoffmann-La Roche AG (CH) 2005-10-05 EP disclosed
WO-2004056822-A1 PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-08 WO disclosed
US-20040122029-A1 Novel dihydropyridinone compounds LIU JIN-JUN (US) 2004-06-24 US disclosed
WO-2003076403-A1 1,2-DISUBSTITUDED-6-OXO-3-PHENYL-PIPERIDINE-3-CARBOXAMIDES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2003-09-18 WO disclosed
US-20030171588-A1 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof LION BIOSCIENCE AG (DE) 2003-09-11 US disclosed
CN-1113872-C Tricyclicbenzo [3] isoindole and benzo (h) isoquinoline HOFFMANN LA ROCHE (CH) 2003-07-09 CN disclosed
CN-1243510-A Tricyclicbenzo [3] isoindole and benzo (h) isoquinoline HOFFMANN LA ROCHE (CH) 2000-02-02 CN disclosed
US-4072716-A Bicycloalkane derivatives SCHERING AKTIENGESELLSCHAFT (DT) 1978-02-07 US disclosed
US-4051188-A NOVEL BICYCLOALKANE DERIVATIVES AND THE PRODUCTION THEREOF SCHERING AKTIENGESELLSCHAFT (DT) 1977-09-27 US disclosed
US-4008253-A Bicycloalkanes SCHERING AKTIENGESELLSCHAFT (DT) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240309000-A1 Process for Preparing an FGFR Inhibitor FGFR1, FGFR2, FGFR3 HSP90AB1 1108/4885GAA 1578/4885KDM4E 647/4885
US-20030171588-A1 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof BRD4, BICRA, HDAC6 HSP90AB1 1894/4885GAA 1719/4885KDM4E 407/4885
US-12281110-B2 Processes for preparing an FGFR inhibitor FGFR2, FGFR1, FGFR3 HSP90AB1 1092/4885GAA 1652/4885KDM4E 741/4885
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 HSP90AB1 577/4885GAA 144/4885KDM4E 2775/4885
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FGFR4, FGFR2, FGFR1 HSP90AB1 332/4885GAA 2159/4885KDM4E 1448/4885
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof FGFR4, FGFR2, FGFR1 HSP90AB1 383/4885GAA 2105/4885KDM4E 1375/4885
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors FGFR1, FGFR3, FGFR2 HSP90AB1 577/4885GAA 144/4885KDM4E 2775/4885
US-20040122029-A1 Novel dihydropyridinone compounds FGFR1, FGFR3, FGFR4 HSP90AB1 1276/4885GAA 3016/4885KDM4E 743/4885
US-11999732-B2 P2X3 receptor antagonists P2RX3, P2RX5, P2RX2 HSP90AB1 2843/4885GAA 2415/4885KDM4E 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.